Want to see IN:VENUSREM full AI Analyst Report?

Venus Remedies Limited (VENUSREM) Price & Analysis

1 Followers

VENUSREM Stock Chart & Stats

₹782.25

-₹3.85(-1.26%)

At close: Jan 08 4:00 PM EST

₹782.25

-₹3.85(-1.26%)

Day’s Range― - ―

52-Week Range₹423.70 - ₹2,043.15

Previous CloseN/A

Volume28.34K

Average Volume (3M)2.33K

Market Cap

₹22.89B

Enterprise Value₹23.54B

Total Cash (Recent Filing)₹2.36B

Total Debt (Recent Filing)₹143.80M

Price to Earnings (P/E)22.8

Beta0.78

Next Earnings

Aug 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)52.61

Shares Outstanding13,366,988

10 Day Avg. Volume2,529

30 Day Avg. Volume2,330

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.65

Price to Sales (P/S)1.42

P/FCF Ratio9.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)39.9

Revenue Forecast (FY)₹828.20M

Bulls Say, Bears Say

Bulls Say

Low Leverage & Equity GrowthThe company’s balance sheet shows very low leverage (debt-to-equity ~0.3% in 2025; under ~10% in 2022–2024) and steady equity growth. That durable capital base increases resilience to demand shocks, supports investment in manufacturing capacity or registrations, and preserves strategic optionality without heavy refinancing risk.

Improved Cash GenerationSubstantial improvement in operating and free cash flow in 2026 strengthens the company’s internal funding ability for capex, working capital and product registrations. Historically FCF was a high share of net income (~75%–94%), indicating the business can convert profits to cash, supporting sustainable operations and reinvestment.

Consistent Revenue And Earnings AccelerationSustained top-line growth into 2026, paired with a material net income acceleration to ~1,027.8M, signals improving commercial traction and operational leverage in core anti-infective and hospital portfolios. This trend supports long-term reinvestment capacity and scaling of higher-volume institutional sales.

Bears Say

Margin Visibility LimitedThe 2026 earnings surge lacks detailed margin disclosure and gross margin has fluctuated across periods. Without clear margin drivers it’s difficult to assess sustainability of profits; if margins revert to historical norms, future earnings and cash generation could be materially weaker than headline 2026 results imply.

Choppy Cash ConversionAlthough 2026 cash flow improved, prior years showed OCF below net income and volatile FCF, reflecting working capital swings or capex timing. This uneven conversion complicates forecasting and can force episodic external financing or constrain spending in weaker quarters, reducing predictability of shareholder returns.

Variable Absolute Debt LevelsDespite low leverage ratios, absolute debt has swung up in certain years, implying episodic borrowing. Such variability can increase refinancing or liquidity risk during industry slowdowns or if tender receivables are delayed, making capital planning less stable even if leverage metrics appear conservative on average.

Venus Remedies Limited News

Venus Remedies Clears FY26 Results, Declares Final Dividend and Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited reported its audited financial results...

1M ago

Venus Remedies Posts FY26 Results, Sets AGM and Dividend, Strengthens Governance

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited reported its financial results for...

1M ago

Venus Remedies Declares Final Dividend and Sets August Virtual AGM

The latest update is out from Venus Remedies Limited ( ($IN:VENUSREM) ). Venus Remedies Limited has reported its...

1M ago

Venus Remedies Opens Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an announcement. Venus Remedies Limited has notified the stock exchange...

2M ago

Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) just unveiled an update. Venus Remedies has notified stock exchanges that it...

4M ago

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has notified the...

5M ago

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited ( ($IN:VENUSREM) ) has issued an update. Venus Remedies Limited has announced that, in accordance...

7M ago

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has announced the opening of...

7M ago

Venus Remedies Completes AMR Licensing Milestones with Final Payment

Venus Remedies Limited ( ($IN:VENUSREM) ) has shared an update. Venus Remedies Limited has successfully completed all commercial...

7M ago

Venus Remedies Ensures Compliance with SEBI Regulations

An announcement from Venus Remedies Limited ( ($IN:VENUSREM) ) is now available. Venus Remedies Limited has announced compliance...

9M ago

VENUSREM FAQ

What was Venus Remedies Limited’s price range in the past 12 months?

Venus Remedies Limited lowest stock price was ₹423.70 and its highest was ₹2043.15 in the past 12 months.

What is Venus Remedies Limited’s market cap?

Venus Remedies Limited’s market cap is ₹22.89B.

When is Venus Remedies Limited’s upcoming earnings report date?

Venus Remedies Limited’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.

How were Venus Remedies Limited’s earnings last quarter?

Venus Remedies Limited released its earnings results on May 26, 2026. The company reported ₹35.53 earnings per share for the quarter, beating the consensus estimate of N/A by ₹35.53.

Is Venus Remedies Limited overvalued?

According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Venus Remedies Limited pay dividends?

Venus Remedies Limited pays a Annually dividend of ₹10 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here

What is Venus Remedies Limited’s EPS estimate?

Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Venus Remedies Limited have?

Venus Remedies Limited has 13,366,988 shares outstanding.

What happened to Venus Remedies Limited’s price movement after its last earnings report?

Venus Remedies Limited reported an EPS of ₹35.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.339%.

Which hedge fund is a major shareholder of Venus Remedies Limited?

Currently, no hedge funds are holding shares in IN:VENUSREM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Venus Remedies Limited

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spectrum of therapeutic areas, including treatments for pain and fever, diabetes, bacterial infections, cardiovascular conditions, gastrointestinal disorders, neurological ailments, and oncology. Additionally, it provides solutions for respiratory health, skin and wound care, stress management, and urological issues, alongside essential vitamins, minerals, and nutritional supplements. Venus Remedies is also active in the field of antimicrobial resistance, offering specialized products, and it supplies disinfectants and hand sanitizers. Furthermore, the firm maintains a distinct line of herbal products and offers hormones and iron supplements. Established in 1989, Venus Remedies Limited operates from its headquarters in Panchkula, India.